News & Events

Date Title and Summary Additional Formats
Toggle Summary Stockholders of Vertex Pharmaceuticals Re-elect Directors at Annual Meeting
CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011
CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011
Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011 Cambridge, MA, February 2, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 5, 2007 it will redeem the outstanding $59.6 million aggregate principal amount of
View HTML
Toggle Summary Vertex Pharmaceuticals Reports 2006 Financial Results
Vertex Pharmaceuticals Reports 2006 Financial Results Cambridge, MA, February 1, 2007 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ended December 31, 2006. “2006 was characterized by significant progress across our
View HTML
Toggle Summary Vertex Pharmaceuticals Added to NASDAQ-100 Index
Vertex Pharmaceuticals Added to NASDAQ-100 Index Cambridge, MA, December 11, 2006 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Company will be added to the NASDAQ-100 Index(R), effective with the market open on Monday, December 18, 2006.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2006 Financial Results
- Company Reiterates Anticipated Timeline of Clinical Milestones -
View HTML
Toggle Summary Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study San Francisco, CA, September 28, 2006 -- Data presented today show low rates of virologic failure and antiviral drug resistance with the HIV protease inhibitor LEXIVA boosted with
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, September 20, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common stock. The gross proceeds, before commissions and
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, September 14, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common stock at a price of $33.00 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, September 11, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 8,000,000 shares of its newly issued common stock in an underwritten public offering.
View HTML
Toggle Summary Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet
LEXIVA(R)/r Twice-Daily Provided Comparable Efficacy to Kaletra Twice-Daily in Treatment-Naive HIV Patients
View HTML
Toggle Summary Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens
Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior
View HTML
Toggle Summary Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
View HTML
Toggle Summary GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and
View HTML
Toggle Summary Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
- Company Updates Corporate Governance Practices -
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
–– Company on Track to Achieve Clinical, Research and Corporate Objectives ––
View HTML
Toggle Summary Vertex Pharmaceuticals Reports 2005 Financial Results
- Clinical, Research and Financial Objectives Achieved -
View HTML
Toggle Summary Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
-Product Candidates with Transformational Potential Highlighted-
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
—Product Candidates with Transformational Potential Highlighted—
View HTML
Toggle Summary VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon
--Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-950 and peg-IFN in 14-day clinical study--
View HTML
Toggle Summary GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir
- Positive Data Presented at 45th Annual ICAAC -
View HTML
Toggle Summary GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
- VX-409 is first in a new class of subtype selective ion channel modulators -
View HTML
Toggle Summary GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
- VX-409 is first in a new class of subtype selective ion channel modulators -
View HTML
Toggle Summary FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
View HTML
Toggle Summary Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
- Investigational New Drug Application Activated in the U.S. -
View HTML
Toggle Summary FDA Approves Updated Labeling for LEXIVA
- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -
View HTML
Toggle Summary FDA Approves Updated Labeling for LEXIVA
- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations
Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results
- VX-950 Phase Ib Combination Study Initiated -<BR> - Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results
Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was
View HTML
Toggle Summary Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy
- Combination of Lexiva/r and Truvada Evaluated -
View HTML
Toggle Summary Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis
- Combination of Lexiva/r and Truvada Evaluated -
View HTML
Toggle Summary FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385)
- GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, June 7, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the pricing of its public offering of 11,750,000 shares of its common stock at a price of $13.00 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, May 31, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 9,500,000 shares of its newly issued common stock in an underwritten public offering.
View HTML
Toggle Summary Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
-- Eugene Cordes, Ph.D., Appointed to Vertex's Board of Directors --
View HTML
Toggle Summary New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium
New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium Quebec City, April 29, 2005 --Today GlaxoSmithKline (GSK) presented new pharmacokinetic (PK) data on taking the HIV protease inhibitor LEXIVA(R) (fosamprenavir calcium, FPV) Tablets with the proton pump inhibitor (PPI), Nexium(R)
View HTML
Toggle Summary New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir
New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir Quebec City, April 29, 2005 --Today new study results announced by GlaxoSmithKline showed the pharmacokinetics (PK) of the HIV protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed in combination with
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update
Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update Cambridge, MA, April 26, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended March 31, 2005.
View HTML
Toggle Summary Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals
Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals Cambridge, MA, February 23, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States District Court for the District of Massachusetts has granted its motion to dismiss a
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance
Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Two Senior Management Changes
Vertex Pharmaceuticals Announces Two Senior Management Changes Cambridge, MA, February 8, 2005 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Dr. Vicki Sato will retire as President of the Company effective during the second quarter of 2005. Dr.
View HTML
Toggle Summary Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference
Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005
View HTML